These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Deshpande D; Srivastava S; Meek C; Leff R; Hall GS; Gumbo T Antimicrob Agents Chemother; 2010 Jun; 54(6):2534-9. PubMed ID: 20385862 [TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. van Ingen J; Egelund EF; Levin A; Totten SE; Boeree MJ; Mouton JW; Aarnoutse RE; Heifets LB; Peloquin CA; Daley CL Am J Respir Crit Care Med; 2012 Sep; 186(6):559-65. PubMed ID: 22744719 [TBL] [Abstract][Full Text] [Related]
5. Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. Deshpande D; Pasipanodya JG; Gumbo T Antimicrob Agents Chemother; 2016 Apr; 60(4):2157-63. PubMed ID: 26810646 [TBL] [Abstract][Full Text] [Related]
6. Dosing ethambutol in obese patients. Alffenaar JW; van der Werf T Antimicrob Agents Chemother; 2010 Sep; 54(9):4044; author reply 4044-5. PubMed ID: 20716782 [No Abstract] [Full Text] [Related]
7. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635 [TBL] [Abstract][Full Text] [Related]
8. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. Deshpande D; Srivastava S; Pasipanodya JG; Lee PS; Gumbo T J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i30-i35. PubMed ID: 28922807 [TBL] [Abstract][Full Text] [Related]
9. Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. Ruth MM; Magombedze G; Gumbo T; Bendet P; Sangen JJN; Zweijpfenning S; Hoefsloot W; Pennings L; Koeken VACM; Wertheim HFL; Lee PS; van Ingen J; Deshpande D J Antimicrob Chemother; 2019 Jul; 74(7):1952-1961. PubMed ID: 31039251 [TBL] [Abstract][Full Text] [Related]
10. Mycobacterium avium complex develop resistance to synergistically active drug combinations during infection. Hoffner SE; Heurlin N; Petrini B; Svenson SB; Källenius G Eur Respir J; 1994 Feb; 7(2):247-50. PubMed ID: 8162976 [TBL] [Abstract][Full Text] [Related]
11. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931 [TBL] [Abstract][Full Text] [Related]
12. Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance. Srivastava S; Deshpande D; Gumbo T J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i20-i23. PubMed ID: 28922805 [TBL] [Abstract][Full Text] [Related]
14. Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases. Deshpande D; Srivastava S; Musuka S; Gumbo T Antimicrob Agents Chemother; 2016 Aug; 60(8):4652-8. PubMed ID: 27216055 [TBL] [Abstract][Full Text] [Related]
15. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs]. Tomioka H; Sato K; Saito H Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791 [TBL] [Abstract][Full Text] [Related]
16. Killing by antimycobacterial agents of AIDS-derived strains of Mycobacterium avium complex inside cells of the mouse macrophage cell line J774. Yajko DM; Nassos PS; Sanders CA; Hadley WK Am Rev Respir Dis; 1989 Nov; 140(5):1198-203. PubMed ID: 2817581 [TBL] [Abstract][Full Text] [Related]
17. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070 [TBL] [Abstract][Full Text] [Related]
18. [Resistance testing of M. avium-intracellulare and M. tuberculosis of AIDS patients with new drugs and drug combinations]. Mauch H; Reichert B; Ruf B; Brehmer W Pneumologie; 1990 Feb; 44 Suppl 1():504-6. PubMed ID: 2114636 [TBL] [Abstract][Full Text] [Related]
19. Linezolid as treatment for pulmonary Mycobacterium avium disease. Deshpande D; Srivastava S; Pasipanodya JG; Gumbo T J Antimicrob Chemother; 2017 Sep; 72(suppl_2):i24-i29. PubMed ID: 28922806 [TBL] [Abstract][Full Text] [Related]
20. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Gumbo T Antimicrob Agents Chemother; 2010 Apr; 54(4):1484-91. PubMed ID: 20086150 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]